Stock News

UPDATE 1-FDA approves Eli Lilly's blood cancer drug
U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
Is It Too Late to Buy Eli Lilly Stock?
Why the Dip in Cassava Sciences (SAVA) Stock Shouldn’t Spook You
2 Ultra-Safe Dividend Stocks to Own in 2023

As seen on...